<DOC>
	<DOCNO>NCT01687712</DOCNO>
	<brief_summary>The purpose study show AFOLIA , recombinant manufacture human follicle stimulate hormone ( r-hFSH ) similar efficacy safety profile compare widely use market r-hFSH Gonal-f .</brief_summary>
	<brief_title>Phase III Study Comparing Efficacy Safety AFOLIA v Gonal-f® Women ( 35 42 ) Undergoing IVF</brief_title>
	<detailed_description>Comparison clinical pregnancy rate AFOLIA group compare Gonal-f group primary endpoint . Comparison number size follicle , number cycle cancellation , hormone parameter adverse event AFOLIA group compare Gonal-f group secondary endpoint .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>35 42 year age Indication control ovarian stimulation IVF intracytoplasmic sperm injection ( ICSI ) Regular menstrual cycle ( 2535 day ) History maximum two fresh cycle treatment present series assist reproductive technology ( ART ) day first screen ( thawed cycle subject criterion ) Body mass index ( BMI ) ≥18 ≤38 kg/m2 Basal FSH &lt; 12 IU/L ( cycle day 25 ) Antral follicle count ( AFC ) ≥ 10 ≤20 follicle diameter &lt; 11mm ( sum ovary ) measure ultrasound ( US ) early follicular phase ( menstrual cycle day 25 ) Documented history infertility due follow factor : tubal factor , mild endometriosis ( American Society Reproductive Medicine [ ASRM ] stage 12 ) , male factor , unexplained infertility Presence ovaries ultrasonography normal uterine cavity ( confirm hysterosalpingography , saline infusion sonography hysteroscopy within 6 month randomization ) Male partner semen analysis least adequate ICSI within 6 month prior patient begin downregulation ( invasive surgical sperm retrieval , donor and/or cryopreserved sperm may use ) Willingness participate study comply study protocol Signed informed consent prior screen Presence pregnancy History active polycystic ovary syndrome ( PCOS ) AFC &gt; 20 follicle diameter &lt; 11 mm ( ovary combine ) measure US early follicular phase ( menstrual cycle day 25 ) History &gt; 2 unsuccessful fresh ART retrieval cycle Presence uncontrolled endocrine disorder Previous history presence severe OHSS Intrauterine fibroid ≥5 cm otherwise clinically relevant pathology could impair embryo implantation pregnancy continuation History recurrent spontaneous abortion ( 3 , even unexplained ) Presence severe endometriosis ( ASRM stage 3 stage 4 ) hydrosalpinx Neoplasia , include tumor hypothalamus pituitary gland Abnormal bleeding undetermined origin History extrauterine pregnancy previous 3 month Known allergy hypersensitivity progesterone excipients ( include peanut oil ) additional study medication ( GnRH agonist , Ovidrel® , Crinone 8 % ® ) History poor response gonadotropin treatment ( define few 5 oocyte retrieve previous attempt ) Any hormonal treatment within 1 month start FSH treatment , exception levothyroxine ) Egg donor Administration investigational product within previous month Clinically abnormal finding Visit 1 Concomitant participation another study protocol</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>IVF</keyword>
	<keyword>In vitro fertilization</keyword>
	<keyword>Controlled ovarian stimulation</keyword>
	<keyword>Follitropin</keyword>
	<keyword>AFOLIA</keyword>
	<keyword>Finox</keyword>
</DOC>